– The partners are joining forces around the world to improve the lives of millions of Parkinson’s patients with a transformative technology-based solution
– Gerresheimer participates in Finnish MedTech and university spin-off seed round
– Combining monitoring and personalized medication adjustment is a novelty
DÜSSELDORF, Germany and KUOPIO, Finland, June 13, 2022 / PRNewswire / – Gerresheimer AG and Adamant Health Oy, a Finnish startup from MedTech, are teaming up to develop a life-changing solution for millions of people around the world with Parkinson’s disease. Developing measurement technologies and platforms will address one of the biggest challenges in treating Parkinson’s symptoms: determining the best time to take medication to relieve symptoms. In the future, Adamant Health’s measurement and analysis technology and Gerresheimer’s digital platform solution will help determine the exact timing of drug delivery and inform patients and medical staff about the patient’s treatment and development of symptoms. Advantage for patients: Symptoms are much more stable and predictable. This will allow them to live a more independent, safe and satisfying way of life.
“Our common goal is to optimize Parkinson’s treatment and significantly improve the patient’s quality of life,” he said. Dietmar SiemssenCEO of Gerresheimer AG. “The investment is part of our strategic deployment in platform-based customized delivery devices combined with digital disease monitoring. In addition, the formula for our strategic process will complement the value-added solution offering for customers defined in G,” he added.
Parkinson’s disease is a progressive disorder of the nervous system that causes recurrent tremors, stiffness, and slow motion. Although currently incurable, medication can significantly relieve symptoms. The disease affects approximately 10 million patients worldwide.
“We expect that the number of people with Parkinson’s will more than double in the next 30 years,” he said. Paul Carpelan, CEO Adamant Health Oy. “Our measurement and analysis service aims to help individualize therapy with its unique technologies and, as a result, significantly improve patients’ quality of life, ”he added.
Adamant Health is a new company and a spinoff company Eastern Finland. It aims to revolutionize Parkinson’s therapy, based on 15 years of academic research. The company applies scientific approaches to the individual analysis of neuromuscular functions and movement.
Gerresheimer has participated in Adamant Health’s seed round and is a major industry partner in this round.
Together, Gerresheimer and Adamant Health fill a gap in the therapy of Parkinson’s patients. Combining monitoring and personalized medication adjustment is a novelty. In the field of chronic neurodegenerative disease monitoring, Adamant Health already has a unique position: the current technologies used to control the progression of the disease only collect data on the patient’s physical movement. The sensor used in Adamant Health’s solution relates this function to a technology called surface electromyography (EMG), which is a local measurement of electrical neuromuscular activity.
Parkinson’s disease is caused by the death of certain nerve cells in the brain. This leads to a lack of the neurotransmitter dopamine. Among other things, dopamine plays an important role in controlling muscle function and therefore movement. The goal of drug treatment is to normalize the concentration of this neurotransmitter. To achieve this, the medication must be carefully set and adjusted on a regular basis. This is made possible by micro-pumps such as the D-Mine pump in Gerresheimer.
Adamant Health’s technology is designed for widespread use for the benefit of all people with Parkinson’s disease, for the development of medication and for research. The partnership aims to combine this technology with customized medical treatment solutions, such as an existing pump manufactured by Gerresheimer and beyond, available to all Parkinson’s patients. This allows for real-time data collection and analysis, and accurate and continuous adjustment of drug application at home. A solution that will significantly improve the lives of millions of affected people.
Gerresheimer is a global partner in pharmacy, biotechnology, healthcare and cosmetics with a wide range of products for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution from concept to final product delivery. Gerresheimer achieves its ambitious goals in terms of innovative strength, industrial capability and quality, and customer focus. To develop innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers. EuropeAmerica and Asia. Gerresheimer produces close to its customers with around 10,000 employees worldwide and in 2021 generated annual revenue. 1.5 million euros. With its products and solutions, Gerresheimer plays a vital role in people’s health and well-being.
Adamant Health Ltd. is a research-based healthcare technology company focused on developing and providing measurement and analysis services for Parkinson’s disease and other movement disorders. The new technology is based on more than 15 years of research and clinical trials conducted at the University Eastern Finland. Adamant Health’s mission is to bring research findings to the benefit of people with movement disorders by enabling physicians, pharmaceutical companies, and researchers to base their work on objective and accurate data from real-world patients measured in patients ’daily lives.
Group CEO Marketing and Communications
+49 211 6181-250
Contact Investor Relations
Corporate General Manager for Investor Relations
+49 211 6181-220
Contact Adamant Health Oy
Adamant Health Oy CEO
+358 50 486 7516
SOURCE Gerresheimer AG